{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eloxatin+Injectable+Product", "query": { "intervention": "Eloxatin Injectable Product" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eloxatin+Injectable+Product&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T02:17:53.772Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00911170", "title": "PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer", "Colon Cancer", "Colorectal Cancer", "Fever", "Locally Advanced", "Metastatic Colorectal Cancer", "Neutropenia", "Rectal Cancer" ], "interventions": [ { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Standard Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 847, "start_date": "2009-11-03", "completion_date": "2015-01-02", "has_results": true, "last_update_posted_date": "2017-12-29", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 72, "location_summary": "Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Modesto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00911170" }, { "nct_id": "NCT05870800", "title": "Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Colon Cancer", "Stage II Colon Cancer", "Stage III Colon Cancer" ], "interventions": [ { "name": "Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2", "type": "DRUG" }, { "name": "Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2", "type": "DRUG" }, { "name": "Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 28, "start_date": "2025-06-15", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05870800" }, { "nct_id": "NCT00077233", "title": "FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 238, "start_date": "2003-12", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2018-05-16", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 77, "location_summary": "Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077233" }, { "nct_id": "NCT07059611", "title": "Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Esophageal Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "RP2", "type": "BIOLOGICAL" }, { "name": "5-Fluorouracil", "type": "COMBINATION_PRODUCT" }, { "name": "Leucovorin", "type": "COMBINATION_PRODUCT" }, { "name": "Oxaliplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Docetaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Surgical Resection of Primary Tumor", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT", "DRUG", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2026-09-01", "completion_date": "2029-11-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07059611" }, { "nct_id": "NCT03362177", "title": "Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-induced Thrombocytopenia" ], "interventions": [ { "name": "Romiplostim", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 165, "start_date": "2019-09-30", "completion_date": "2025-01-09", "has_results": true, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 22, "location_summary": "Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03362177" }, { "nct_id": "NCT03563157", "title": "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic", "mCRC" ], "interventions": [ { "name": "Aldoxorubicin Hydrochloride", "type": "BIOLOGICAL" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-09-28", "completion_date": "2019-08-21", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563157" }, { "nct_id": "NCT06692907", "title": "Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Escherichia Infection" ], "interventions": [ { "name": "B7A (ETEC challenge strain)", "type": "OTHER" }, { "name": "CssBA", "type": "BIOLOGICAL" }, { "name": "dmLT", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 72, "start_date": "2025-03-31", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Cincinnati, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06692907" }, { "nct_id": "NCT07228832", "title": "Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer (CRC)" ], "interventions": [ { "name": "Drug: Ivonescimab Injection", "type": "DRUG" }, { "name": "Drug: Bevacizumab Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2025-11-18", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 102, "location_summary": "Mobile, Alabama • Tuscaloosa, Alabama • Goodyear, Arizona + 85 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07228832" }, { "nct_id": "NCT00659269", "title": "A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Multivitamin (MV)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Multivitamin + Vitamin B12 + Vitamin B6", "type": "DIETARY_SUPPLEMENT" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "New Mexico Cancer Research Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 319, "start_date": "2006-07", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-02-26", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 5, "location_summary": "Albuquerque, New Mexico • Santa Fe, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Santa Fe", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00659269" }, { "nct_id": "NCT04083235", "title": "A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Adenocarcinoma of the Pancreas" ], "interventions": [ { "name": "Irinotecan Liposomal Injection", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 770, "start_date": "2020-02-11", "completion_date": "2025-02-18", "has_results": true, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-09T02:17:53.772Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083235" } ] }